FDA and FTC issue warning letters to companies selling fraudulent COVID-19 products
The US agencies have issued letters to seven companies, and removed online listings from others, whose products falsely claim to prevent or treat coronavirus.
List view / Grid view
The US agencies have issued letters to seven companies, and removed online listings from others, whose products falsely claim to prevent or treat coronavirus.
The UK’s Competition and Markets Authority (CMA) has fined four companies in because of anti-competitive practices in the supply of nortriptyline.
Research has shown that the CAR-T therapies in development in Asia-Pacific will make the worldwide market more competitive and drive down prices.
The developers of givosiran announced the European Commission (EC) has granted the drug marketing authorisation based on results of the Phase III ENVISION trial.
A study of over 602 brand-name prescription drugs shows that list prices increased over 1.5 times and net prices rose over 3.5 times inflation in the past decade.
A report has suggested that number of Orphan Drug Designations in both the US and Europe is declining, possibly due to prices and political changes.
The UK government has changed the restrictions on importing cannabis-based medicine products into the country, allowing wholesalers to bring in larger quantities.
The FDA has released a statement, announcing that the US is experiencing its first shortage as a result of the effects of COVID-19.
The EMA has recommended granting marketing authorisation to two medicines and extending the indications for three more following its latest meeting.
Advil Dual Action is the first FDA-approved an over-the-counter ibuprofen and acetaminophen combination, backed up with data from several clinical trials proving its efficacy.
Ranitidine tablets have been recalled due to the possibility of the products containing unacceptable levels of NDMA.
The US NIH has initiated a clinical trial for remdesivir and two pharmaceutical companies will work together to manufacture antibody treatments to tackle the coronavirus.
European Pharmaceutical Review investigates five of the latest cancer drug approvals and clinical trial results.
A report has revealed that the products in the pipeline to treat dry eye syndrome are expected to expand the number of options available for patients.
Once patents expire for biologic medicines, a market opportunity opens up for biosimilars, a cheaper alternative. With more patents due to expire soon, what will the future look like for biologic medicines?